News Releases

Jun 23, 2022
Myriad Genetics Teams Up with Epic to Make Genetic Testing Accessible to More Patients with Electronic Health Record (EHR) Integration
Pipeline
Apr 26, 2022
2 Out of 3 Women With Depression or Anxiety Say They’ve Reached Their “Breaking Point” Yet More than Half Wait a Year Before Seeking Treatment
Products
Mar 14, 2022
Myriad Genetics Advances Precision Oncology with New Precise™ Solutions, Combines Genetic Insights from Multiple Tests to Guide Treatment Decisions and Improve Patient Care
Corporate
Mar 11, 2022
Myriad Genetics Receives FDA Approval of BRACAnalysis® CDx as a Companion Diagnostic for Lynparza® in Early Breast Cancer
Products
Feb 23, 2022
New Analysis Published in Peer-reviewed Psychiatry Research Shows Advantages of Combinatorial Algorithm of GeneSight® Psychotropic Test
Products
Dec 15, 2021
New Year’s Resolutions: Americans Say Body & Mind Equally Important in Theory but Not in Practice, According to GeneSight® Mental Health Monitor Nationwide Survey
Products
Nov 23, 2021
The New Generation Gap: Nationwide Survey Finds Different Perspectives on Anxiety Between Parents, Young Adults
Products
Nov 22, 2021
Myriad Genetics to Present New Data at San Antonio Breast Cancer Symposium Highlighting Value of Genetic Testing in Breast Cancer Risk Assessment and Treatment
Pipeline
Oct 11, 2021
Americans’ anxiety impacted by the ongoing pandemic, yet 1 in 5 say they won’t seek treatment according to the GeneSight® Mental Health Monitor nationwide survey
Products
Sep 08, 2021
Only 8% of people remain hopeful after depression medication fails them, according to GeneSight® Mental Health Monitor nationwide survey
Products
Aug 02, 2021
Myriad Genetics Expands Access to Genetic Testing with Launch of First Polygenic Breast Cancer Risk Assessment Score Validated for Women of All Ancestries
Pipeline
Jul 28, 2021
New research reveals most Americans can’t identify the symptoms of depression
Products
Jul 21, 2021
Myriad Genetics Supports New ACMG Recommendation Statement on Increasing Access to Carrier Screening for All Ethnicities
Corporate
Jun 01, 2021
Myriad Genetics Completes the Sale of Myriad myPath® Melanoma, LLC, Laboratory to Castle Biosciences
Corporate
May 19, 2021
Myriad Genetics to Share New Data at 2021 ASCO Validating Personalized Breast Cancer Risk Assessments for Women of All Ancestries
Pipeline